Building translational evidence systems that connect mechanistic biology, scientific communication, and AI-enabled biomedical insight.
From the mechanism of resistance to the message that moves a program forward — I build the evidence, translate it, and make it usable for the people who decide.
I build mechanism-first platforms — from FtsZ chemical biology and antimicrobial pharmacology to biofilm, microbiome, and 3D-tissue models — that turn biological complexity into decision-grade, translational evidence.
I translate complex data into clear, credible narratives — claims substantiation, technical briefs, evidence synthesis, and KOL-ready insight — adapting depth for scientists, regulators, commercial teams, and leadership.
I use LLM workflows, Python/R pipelines, and structural tools like AlphaFold to accelerate literature synthesis, QC, and biomedical reasoning — without replacing scientific judgment — so teams move faster and think more clearly.
A cross-section of platforms built to connect mechanism, translational evidence, scientific communication, and real-world decisions.
Translating complex biomedical evidence into decisions, communication, and real-world health impact.
I am a Ph.D. scientist working at the intersection of mechanistic biology, translational research, scientific communication, and AI-enabled evidence generation. My career has focused on turning complex biomedical questions into measurable platforms, clear scientific narratives, and evidence packages that support decisions across discovery, regulatory strategy, product development, and health communication.
My foundation is in antimicrobial pharmacology and bacterial cell biology, where I built mechanistic and biophysical workflows to study FtsZ as an antibacterial target in multidrug-resistant pathogens.
In industry, I have expanded that platform-building approach into host-microbiome biology, biofilm science, 3D tissue models, translational endpoints, claims substantiation, and global evidence strategy.
I translate complex biological data into clear narratives for scientific, regulatory, commercial, and leadership audiences, preserving technical rigor while making evidence useful for action.
I am especially interested in responsible AI tools that accelerate literature synthesis, evidence interpretation, study design, and biomedical decision-making to improve medicine and wellbeing.
Across roles, my focus is consistent: build the scientific infrastructure, translate the evidence, and communicate the story clearly enough for action.
I connect mechanism, evidence generation, medical communication, and AI-enabled analysis to help teams move from biological complexity to confident decisions.
I build platforms and narratives that make complex science understandable to researchers, clinicians, business leaders, regulators, and patient-facing teams.
From discovery through patent to commercialization, listed by release year with the newest work first.
Characterization of vulvar microbiome ecology across life stages, health status, and functional signatures.
Novel fluorescent probes designed to target the FtsZ protein for real-time visualization of division machinery. Licensed and commercialized via MilliporeSigma.
Discovery of a benzamide FtsZ inhibitor with strong bactericidal activity and in vivo efficacy against multidrug-resistant MRSA.
Demonstrates how FtsZ inhibition can restore and potentiate beta-lactam performance against MRSA.
Identification of MreB-targeting small molecules with antibacterial activity against Gram-negative pathogens.
Mechanistic study connecting FtsZ inhibition to altered localization of penicillin-binding proteins in MRSA.
Structure-guided probe design enabling visualization of FtsZ across clinically relevant pathogens.
Identifies beta-lactams with high PBP2 affinity that maximize synergy with FtsZ inhibition against MRSA.
Insights on microbiology, scientific practice, and the systems that shape them.
Fetching latest insights from functionalmechanisms.blogspot.com…
Platform ownership examples illustrating transferable, systems-level scientific leadership.
Designing mechanistic and translational platforms to combat antimicrobial resistance by breaking persistence, transmission, and treatment failure across clinical and consumer environments.
Understanding and disrupting microbial systems—biofilms, communities, and host–microbe interactions—to reduce chronic infection risk and improve intervention durability.
Translating molecular and cellular mechanisms into decision-grade evidence that informs therapeutic strategy, candidate selection, and resistance-mitigation approaches.
Building scalable assay systems, analytics, and scientific narratives that turn complex biological data into confident decisions across R&D, regulatory, and product teams.
I build the mechanistic foundation, translate it across audiences, and communicate with the precision that moves things forward.